Literature DB >> 25703191

Glycemic control, inflammation, and cognitive function in older patients with type 2 diabetes.

Jimmy Akrivos1,2, Ramit Ravona-Springer3, James Schmeidler1, Derek LeRoith4,5, Anthony Heymann6, Rachel Preiss6, Hadas Hoffman6, Keren Koifman3, Jeremy M Silverman1,2, Michal Schnaider Beeri1,3,7.   

Abstract

OBJECTIVE: Glycated hemoglobin (HbA1c) and C-reactive protein (CRP) have been associated with cognitive impairment independently. However, it is unclear if their combination exacerbates poor cognitive function. We assessed whether long-term glycemic level and glycemic variability modulate the association of systemic inflammation with cognitive function, in a sample of cognitively normal older people with type 2 diabetes.
METHODS: A retrospective cohort study of 777 randomly selected participants from ~11,000 patients in the Maccabi Healthcare Services Diabetes Registry, as part of the Israel Diabetes and Cognitive Decline study. Subjects averaged 18 (±9.4) HbA1c measures in the Maccabi Healthcare Services Registry, which were used to calculate long-term glycemic level (HbA1c-mean) and glycemic variability (HbA1c-standard deviation (SD)). Linear regression models assessed the interactions of CRP, a marker of systemic inflammation, with HbA1c-mean and HbA1c-SD on subjects' performance in tests of Memory, Executive Functions, Attention, and Semantic Categorization.
RESULTS: Quadratic interactions of CRP with HbA1c-SD approached significance for executive functions and overall cognition. However, after Bonferroni adjustment, none of the interactions of CRP with HbA1c were statistically significant. In partial correlations according to HbA1c-SD tertiles, CRP was weakly correlated in the middle tertile with decreased performance in the domains of semantic categorization (r = -0.166, p = 0.011), executive functions (r = -0.136, p = 0.038), and overall cognition (r = -0.157, p = 0.016).
CONCLUSIONS: Glycated hemoglobin does not substantially modulate the association of CRP with cognition in a sample of cognitively normal, community dwelling older people with relatively well-managed type 2 diabetes.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  C-reactive protein; HbA1c; cognitive function; older people; type 2 diabetes

Mesh:

Substances:

Year:  2015        PMID: 25703191      PMCID: PMC5753409          DOI: 10.1002/gps.4267

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  30 in total

1.  Is HbA(1c) affected by glycemic instability?

Authors:  Rachel Derr; Elizabeth Garrett; Gerald A Stacy; Christopher D Saudek
Journal:  Diabetes Care       Date:  2003-10       Impact factor: 19.112

2.  Inflammatory markers and neuropsychological functioning: the Framingham Heart Study.

Authors:  Angela L Jefferson; Joseph M Massaro; Alexa S Beiser; Sudha Seshadri; Martin G Larson; Philip A Wolf; Rhoda Au; Emelia J Benjamin
Journal:  Neuroepidemiology       Date:  2011-07-13       Impact factor: 3.282

3.  Improved diabetes control in the elderly delays global cognitive decline.

Authors:  J A Luchsinger; W Palmas; J A Teresi; S Silver; J Kong; J P Eimicke; R S Weinstock; S Shea
Journal:  J Nutr Health Aging       Date:  2011-06       Impact factor: 4.075

4.  The relationship between glucose excursion and cognitive function in aged type 2 diabetes patients.

Authors:  Yuan Zhong; Xiao Yan Zhang; Ya Miao; Jie Hua Zhu; Hong Yan; Bei Yun Wang; Jun Jin; Ting Jun Hu; Wei Ping Jia
Journal:  Biomed Environ Sci       Date:  2012-02       Impact factor: 3.118

5.  Long-term assessment of inflammation and healthy aging in late life: the Cardiovascular Health Study All Stars.

Authors:  Nancy S Jenny; Benjamin French; Alice M Arnold; Elsa S Strotmeyer; Mary Cushman; Paulo H M Chaves; Jingzhong Ding; Linda P Fried; Stephen B Kritchevsky; Dena E Rifkin; Mark J Sarnak; Anne B Newman
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-02-24       Impact factor: 6.053

Review 6.  Future directions in Alzheimer's disease from risk factors to prevention.

Authors:  Bushra Imtiaz; Anna-Maija Tolppanen; Miia Kivipelto; Hilkka Soininen
Journal:  Biochem Pharmacol       Date:  2014-01-10       Impact factor: 5.858

7.  Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

Authors:  A Festa; R D'Agostino; G Howard; L Mykkänen; R P Tracy; S M Haffner
Journal:  Circulation       Date:  2000-07-04       Impact factor: 29.690

8.  Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics.

Authors:  A M Abbatecola; M R Rizzo; M Barbieri; R Grella; A Arciello; M T Laieta; R Acampora; N Passariello; F Cacciapuoti; G Paolisso
Journal:  Neurology       Date:  2006-07-25       Impact factor: 9.910

9.  Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes: the Hoorn Study.

Authors:  Jolien de Jager; Jacqueline M Dekker; Adriaan Kooy; Piet J Kostense; Giel Nijpels; Rob J Heine; Lex M Bouter; Coen D A Stehouwer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-03-02       Impact factor: 8.311

10.  The association of duration of type 2 diabetes with cognitive performance is modulated by long-term glycemic control.

Authors:  Rebecca K West; Ramit Ravona-Springer; James Schmeidler; Derek Leroith; Keren Koifman; Elizabeth Guerrero-Berroa; Rachel Preiss; Hadas Hoffman; Jeremy M Silverman; Anthony Heymann; Michal Schnaider-Beeri
Journal:  Am J Geriatr Psychiatry       Date:  2014-01-23       Impact factor: 4.105

View more
  7 in total

1.  Chronic Peripheral Inflammation is Associated With Cognitive Impairment in Schizophrenia: Results From the Multicentric FACE-SZ Dataset.

Authors:  Ewa Bulzacka; Laurent Boyer; Franck Schürhoff; Ophélia Godin; Fabrice Berna; Lore Brunel; Méja Andrianarisoa; Bruno Aouizerate; Delphine Capdevielle; Isabelle Chéreau-Boudet; Gabrielle Chesnoy-Servanin; Jean-Marie Danion; Caroline Dubertret; Julien Dubreucq; Catherine Faget; Franck Gabayet; Tifenn Le Gloahec; Pierre-Michel Llorca; Jasmina Mallet; David Misdrahi; Romain Rey; Raphaëlle Richieri; Christine Passerieux; Paul Roux; Hanan Yazbek; Marion Leboyer; Guillaume Fond
Journal:  Schizophr Bull       Date:  2016-05-03       Impact factor: 9.306

2.  Integrating Frailty and Cognitive Phenotypes: Why, How, Now What?

Authors:  Qian-Li Xue; Brian Buta; Lina Ma; Meiling Ge; Michelle Carlson
Journal:  Curr Geriatr Rep       Date:  2019-04-24

3.  Dopamine Adaptations as a Common Pathway for Neurocognitive Impairment in Diabetes and Obesity: A Neuropsychological Perspective.

Authors:  Dana M Small
Journal:  Front Neurosci       Date:  2017-03-28       Impact factor: 4.677

4.  Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).

Authors:  Bernard Zinman; Steven P Marso; Neil R Poulter; Scott S Emerson; Thomas R Pieber; Richard E Pratley; Martin Lange; Kirstine Brown-Frandsen; Alan Moses; Ann Marie Ocampo Francisco; Jesper Barner Lekdorf; Kajsa Kvist; John B Buse
Journal:  Diabetologia       Date:  2017-09-15       Impact factor: 10.122

Review 5.  Glycemic Variability and CNS Inflammation: Reviewing the Connection.

Authors:  Charles Watt; Elizabeth Sanchez-Rangel; Janice Jin Hwang
Journal:  Nutrients       Date:  2020-12-21       Impact factor: 5.717

6.  Glycemic and lipid variability for predicting complications and mortality in diabetes mellitus using machine learning.

Authors:  Sharen Lee; Jiandong Zhou; Wing Tak Wong; Tong Liu; William K K Wu; Ian Chi Kei Wong; Qingpeng Zhang; Gary Tse
Journal:  BMC Endocr Disord       Date:  2021-05-04       Impact factor: 2.763

Review 7.  The Association between Hepatic Encephalopathy and Diabetic Encephalopathy: The Brain-Liver Axis.

Authors:  So Yeong Cheon; Juhyun Song
Journal:  Int J Mol Sci       Date:  2021-01-05       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.